Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. - Wikidata - awgldk - TriplyDB

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine.

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine.

http://www.wikidata.org/entity/Q45235400

about

Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians Genetics of antipsychotic treatment emergent weight gain in schizophrenia.[Genetics of weight gain associated with antipsychotic medications].Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene.Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication The promise and reality of pharmacogenetics in psychiatry Pharmacogenetics of antipsychotic-induced side effects Genetic Polymorphisms in the HTR2C and Peroxisome Proliferator-Activated Receptors Are Not Associated with Metabolic Syndrome in Patients with Schizophrenia Taking Clozapine Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment.Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis.Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain.Pharmacogenetics of antipsychotics: recent progress and methodological issues.Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.No Association between Serotonin Receptor 2C-759C/T Polymorphism and Weight Change or Treatment Response to Mirtazapine in Korean Depressive Patients.Genomics and the future of pharmacotherapy in psychiatry.Antipsychotic induced weight gain in schizophrenia:mechanisms and management.Obesity, serious mental illness and antipsychotic drugs.Pharmacogenetic considerations in the treatment of psychiatric disorders.Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review.Pharmacogenetics of response to antipsychotics in patients with schizophrenia.Atypical antipsychotic-induced weight gain: insights into mechanisms of action.Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review.Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy.Pharmacogenetics of second-generation antipsychotics.HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis.Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.G-protein beta3 Subunit Gene 825C/T Polymorphism Is Not Associated with Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients.Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study.Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene.Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan.Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia.Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain.

P2860

Q22241430-D8080168-8A4A-4828-BD45-84BC907EF079 Q24657338-601C1799-2089-4059-B2AE-7A2E48BC6E5B Q33257886-0F83EA0A-6019-4960-9488-253EC6F04E8C Q33408581-F4FADF39-97BB-43B8-98AF-2FFDCD22CDEF Q34006864-485931A5-CCFB-44F4-944A-38B40641C6CF Q34413008-1CD315B4-6E99-42AF-92BA-6CA8C667D300 Q34641561-B191C339-7C5A-4DF6-8BC0-0BDB1000BEA7 Q34676533-F74AAC3A-D057-4A04-9C07-D5D5A498C911 Q35064650-1753C82D-46CD-4F83-9776-632EBEAA5ACC Q35226451-FF19353F-EA7E-4D2B-AAA6-9F0C43BCD082 Q35237129-B8CEBCF2-C2FE-4779-ACC1-5B8F60A26437 Q35238354-C145B2F2-CCDC-42DB-94F2-0DB8554A2FAF Q36061639-52171928-2AD7-41DA-A7F7-B2241AB50B03 Q36316001-759DAB40-F745-4275-83F5-67D464F7DE78 Q36433993-51C3553C-A1C9-454A-9310-7C12E006E415 Q36441507-AB4548CB-556D-4102-800D-B82638D3D20E Q36539833-3C3F065B-F9FF-4C65-892C-62692A51AB8B Q36840610-1824B4AA-7B4D-4823-B4AD-9B0228071DEF Q36941595-84773018-49B3-461F-8089-DCB068230241 Q36951758-FC1C0FA7-C011-4BDD-8E5C-3E178AC82958 Q37160453-69CD092E-92F3-409F-81D2-76ED7FBA55CB Q37498921-5FA86AF8-3B78-4EA6-886C-F9B15D36CA7E Q37681573-B7000B9B-8A45-423C-957D-3C4152FC8FD8 Q37917782-6BBC5968-46E5-42EA-B0BF-5F2C7DA3ACBC Q37952823-8E8C41C8-E0A1-4313-817B-F4FDF2E2E318 Q37963571-AB18C196-0CB2-4072-BAD9-F053B6D79DF6 Q38083647-259ED317-16A2-47D2-BC31-49A1CE834D81 Q38154911-A4DAD01B-CC9A-4DE1-8965-3E12425C10B4 Q38217628-C8432007-8A7B-4670-99A1-D3161B6CAF60 Q38242739-46F6124A-8C5F-4D20-B946-D1E33D244037 Q38842714-0DC4BB66-41B7-40F9-9E2A-15A33F5CCF45 Q40255006-71C8D7AA-A15F-4071-8A65-38A0F2A93471 Q42950178-9DE3BBBE-67E6-4E7A-A61F-FC185FAF2C11 Q43053801-50043BCF-BA1F-4A6E-AE67-ABCF9BEE329E Q45252599-B016C5F1-5630-4360-B57A-076D9B47A944 Q45918280-1350A12B-9736-42B5-AF74-49EB17A412C5 Q46015738-FE27D74A-95A4-4B91-905F-6A230B22A149 Q46020169-425E4176-3FFA-4EDA-AAA2-BDB0AF184F95 Q46029869-8DDA6892-9020-4D2A-82A1-C8233742682F Q46356344-1CCAE5BA-279F-4386-941E-0F22FD4776B0

P2860

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine.

http://www.wikidata.org/entity/Q45235400

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Weight gain associated with th ...... 5HT2C receptor and olanzapine.

@en

Weight gain associated with th ...... 5HT2C receptor and olanzapine.

@nl

type

label

Weight gain associated with th ...... 5HT2C receptor and olanzapine.

@en

Weight gain associated with th ...... 5HT2C receptor and olanzapine.

@nl

prefLabel

Weight gain associated with th ...... 5HT2C receptor and olanzapine.

@en

Weight gain associated with th ...... 5HT2C receptor and olanzapine.

@nl

P1433

Q45235400-0DEC3227-F35A-4D65-ADA4-635393322AD6

P1476

Q45235400-3BF28A6E-202C-4AF7-9BCC-56421699BDB4

P2093

Q45235400-1F4FA589-BA66-43B5-B6EB-08F58400896E

Q45235400-44AADBC9-0B71-48DA-8185-A8A7318FC725

Q45235400-46BE22CA-D850-4C54-8B81-B25DC5CAD083

Q45235400-5500613D-A905-4C4B-A6B9-549D5354BB1E

Q45235400-97580893-14E6-4A8E-A761-2DC01391FE7C

Q45235400-B0966107-4F63-4087-9502-E0632DF58E24

Q45235400-C1978C1A-F4E9-46F5-A1C0-A26D9A0A044B

Q45235400-F6E3DF21-8531-4301-A833-E2BD401F7877

P2860

Q45235400-1DA0BB25-E576-457B-82C2-DF1BD03359F9

P304

Q45235400-A2AA99C7-688B-454B-9DC0-AE60539DAC98

P31

Q45235400-914A79FC-DD5C-496D-B938-D6C36BF7D9A1

P356

Q45235400-B5767D61-4E3A-4EDF-9B3B-B97B33EBE862

P433

Q45235400-1BFB6FBC-C90B-41E8-8ABD-D55E85746AD5

P478

Q45235400-8303E99D-5F1C-4694-A0FB-0868C99605ED

P577

Q45235400-57396B1D-B23C-43E1-96CE-07AD354B45C0

P698

Q45235400-073CB005-947B-4274-B8F6-DDEB8EF7485F

P921

Q45235400-CEADE4D8-A426-413E-88CE-E4BE967303A6

P356

P1433

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics

P1476

Weight gain associated with th ...... 5HT2C receptor and olanzapine.

@en

P2093

Brian C Lund

http://www.w3.org/2001/XMLSchema#string

Del Miller

http://www.w3.org/2001/XMLSchema#string

Frank Fleming

http://www.w3.org/2001/XMLSchema#string

John C Ringold

http://www.w3.org/2001/XMLSchema#string

Kristy Bever-Stille

http://www.w3.org/2001/XMLSchema#string

Paul J Perry

http://www.w3.org/2001/XMLSchema#string

Timothy L Holman

http://www.w3.org/2001/XMLSchema#string

Vicki L Ellingrod

http://www.w3.org/2001/XMLSchema#string

P2860

Medical complications of new antipsychotic drugs.

P304

76-78

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJMG.B.20169

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

134B

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15666332

http://www.w3.org/2001/XMLSchema#string

P921